Request Demo
Last update 20 Jun 2026
QLS1304
Last update 20 Jun 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms QLS1304 |
Target |
Action inhibitors |
Mechanism KAT6A inhibitors(lysine acetyltransferase 6A inhibitors), KAT6B inhibitors(lysine acetyltransferase 6B inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (United States) |
Login to view timeline
Related
2
Clinical Trials associated with QLS1304NCT07235176
A Phase Ib/II Clinical Study to Evaluate Safety, Preliminary Efficacy and PK Characteristic of QLS1304 Combined With Endocrine Therapy in ER+/HER2- Breast Cancer Patients
NCT06823609
A Phase I Clinical Study to Evaluate Safety, Tolerability, PK Characteristic and Preliminary Efficacy of QLS-1304 in Patients With Advanced Malignant Tumors
100 Clinical Results associated with QLS1304
Login to view more data
100 Translational Medicine associated with QLS1304
Login to view more data
100 Patents (Medical) associated with QLS1304
Login to view more data
100 Deals associated with QLS1304
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced breast cancer | Phase 2 | China | 16 Jan 2026 | |
| ER-positive/HER2-negative Breast Cancer | Phase 2 | China | 03 Dec 2025 | |
| Advanced cancer | Phase 1 | China | 06 Mar 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 14 Feb 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Human epidermal growth factor 2 negative carcinoma of breast | Estrogen receptor positive tumor estrogen receptor-positive (ER+) | human epidermal growth factor receptor 2-negative (HER2−) | 33 | pdyhnugpiq(gdbmkupycu) = bwdjqwqgsk xxxktticmv (eajazeccnm ) | Positive | 29 May 2026 | ||
QLS1304 + QLC1401 | pdyhnugpiq(gdbmkupycu) = twopsjjpff xxxktticmv (eajazeccnm ) | ||||||
Not Applicable | KAT6A amplification | H3K23Ac | ER expression ... View more | - | dpgzdqhcop(dflczxrlzq) = suppressed in KAT6A-high cells bgdefnwidk (wshhhyyhqc ) View more | - | 27 Apr 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free